Study demonstrates safety and efficacy of a three-dose whole-parasite vaccine against malaria

A three-dose regimen of a whole-parasite vaccine against malaria – called Plasmodium falciparum sporozoite (PfSPZ) vaccine – demonstrated safety and efficacy when tested in adults living in Burkina Faso, West Africa, which has endemic malaria.

Related Keywords

Burkina Faso ,Tanzania ,Kirstene Lyke ,Biraj Shrestha ,Deanmarkt Gladwin ,David Clyde ,Emily Henderson ,Akikok Bowers ,Sudhaunshu Joshi ,Matthewb Laurens ,Kathy Strauss ,University Of Maryland ,United Nations ,Malaria Research Group ,Laboratory Specialist ,University Of Maryland School Medicine Center ,Global Health ,Sanaria Inc ,Laboratory Specialis ,Vaccine Development ,International Clinical Trials Unit ,West Africa ,Science Translational ,Maryland School ,World Health Organization ,Study Corresponding Author ,Maryland Based Sanaria ,Industry Focus ,Vice President ,Medical Affairs ,Laboratory Assistant ,Efficacy ,Malaria ,Vaccine ,Clinical Trial ,Diarrhea ,Fever ,Immunity ,Infectious Diseases ,Laboratory ,Medicine ,Ediatrics ,Placebo ,Plasmodium Falciparum ,Research ,Typhoid ,